Mar 31, 2017

Oncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer

Mar 16, 2017

Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma

Mar 10, 2017

Oncolytics Biotech® Inc. Announces 2016 Year-End Results

Mar 2, 2017

Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting

Jan 19, 2017

Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO

Dec 6, 2016

Oncolytics Biotech® Inc. Announces Change to Board of Directors

Dec 6, 2016

Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting

Nov 10, 2016

Oncolytics Biotech® Inc. Announces Appointment of New Chief Medical Officer

Nov 3, 2016

Oncolytics Biotech® Inc. Announces 2016 Third Quarter Results

Nov 2, 2016

Media Advisory - Oncolytics Biotech® Inc. Announces Management Team Changes